P Peter Ghoroghchian
Overview
Explore the profile of P Peter Ghoroghchian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Detappe A, Nguyen H, Jiang Y, Agius M, Wang W, Mathieu C, et al.
Nat Nanotechnol
. 2023 Aug;
18(9):1116.
PMID: 37563269
No abstract available.
2.
Detappe A, Nguyen H, Jiang Y, Agius M, Wang W, Mathieu C, et al.
Nat Nanotechnol
. 2023 Mar;
18(4):419.
PMID: 36914884
No abstract available.
3.
Detappe A, Nguyen H, Jiang Y, Agius M, Wang W, Mathieu C, et al.
Nat Nanotechnol
. 2023 Jan;
18(2):184-192.
PMID: 36702954
Cancer therapies often have narrow therapeutic indexes and involve potentially suboptimal combinations due to the dissimilar physical properties of drug molecules. Nanomedicine platforms could address these challenges, but it remains...
4.
Nguyen H, Detappe A, Harvey P, Gallagher N, Mathieu C, Agius M, et al.
Polym Chem
. 2021 Apr;
11(29):4768-4779.
PMID: 33790990
Nitroxide-based organic-radical contrast agents (ORCAs) are promising as safe, next-generation magnetic resonance imaging (MRI) tools. Nevertheless, stimuli-responsive ORCAs that enable MRI monitoring of prodrug activation have not been reported; such...
5.
Ghoroghchian P, Lin J, Brannan A, Frail P, Bates F, Therien M, et al.
Soft Matter
. 2020 Jul;
2(11):973-980.
PMID: 32680185
We utilize a series of structurally homologous, multi-porphyrin-based, fluorophores (PBFs) in order to explore the capacity of polymer vesicles (polymersomes) to stably incorporate large hydrophobic molecules, non-covalently within their thick...
6.
Qi R, Wang Y, Bruno P, Xiao H, Yu Y, Li T, et al.
Nat Commun
. 2020 Apr;
11(1):1940.
PMID: 32303677
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
7.
Detappe A, Reidy M, Yu Y, Mathieu C, Nguyen H, Coroller T, et al.
Nanoscale
. 2019 Oct;
11(43):20485-20496.
PMID: 31650133
Monitoring malignant progression and disease recurrence post-therapy are central challenges to improving the outcomes of patients with multiple myeloma (MM). Whereas current detection methods that rely upon bone marrow examination...
8.
Nguyen H, Detappe A, Gallagher N, Zhang H, Harvey P, Yan C, et al.
ACS Nano
. 2018 Nov;
12(11):11343-11354.
PMID: 30387988
Nitroxides occupy a privileged position among plausible metal-free magnetic resonance imaging (MRI) contrast agents (CAs) due to their inherently low-toxicity profiles; nevertheless, their translational development has been hindered by a...
9.
Panchamoorthy G, Jin C, Raina D, Bharti A, Yamamoto M, Adeebge D, et al.
JCI Insight
. 2018 Jun;
3(12).
PMID: 29925694
Mucin 1 (MUC1) is a heterodimeric protein that is aberrantly overexpressed on the surface of diverse human carcinomas and is an attractive target for the development of mAb-based therapeutics. However,...
10.
Detappe A, Bustoros M, Mouhieddine T, Ghoroghchian P
Trends Mol Med
. 2018 May;
24(6):560-574.
PMID: 29773319
In the past decades, considerable progress has been made in our understanding and treatment of multiple myeloma. Several challenges remain including our abilities to longitudinally image tumor responses to treatment,...